The mining company is developing and seeking a partner to advance its large-scale, British Columbia mine offering long-term upside potential, noted an RBC Capital Markets report.
The company that recently updated the mineral resource estimate of its project in British Columbia offers investors a compelling, 233% return, noted a Noble Capital Markets report.
This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report.
Now that its processing plant in Mexico is nearing nameplate capacity, BMO Capital Markets reinstated coverage on this company, which it says has "strong cash flows on the way."
The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.
The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years, noted an H.C. Wainwright & Co. report.
By drilling this and future wells, the oil and gas firm is "looking to unlock the potential of the Abu Roash F formation," noted a Research Capital Corp. report.
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report.
The highlight is the discovery of a new area of gold mineralization, which further demonstrates the potential over the land package, noted a PI Financial report.